EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Lowered

EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its target price reduced by HC Wainwright from $35.00 to $33.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q4 2023 earnings at ($0.40) EPS, FY2023 earnings at ($1.89) […]

Related Keywords

, Eyepoint Pharmaceuticals Inc , Securities Exchange Commission , Analyst Recommendations For Eyepoint Pharmaceuticals , Eyepoint Pharmaceuticals Stock Performance , Eyepoint Pharmaceuticals , Jpmorgan Chase Co , Institutional Trading Of Eyepoint Pharmaceuticals , York Mellon Corp , Blackrock Inc , News Ratings For Eyepoint Pharmaceuticals Daily , Metlife Investment Management , Free Report , Capital One Financial , Moderate Buy , Point Pharmaceuticals , Get Free Report , Director Ye Liu , Exchange Commission , Cormorant Asset Management , New York Mellon Corp , Life Investment Management , Eyepoint Pharmaceuticals Daily , Nasdaq Eypt , Eypt , Medical , Lower Price Target , Hc Wainwright ,